|Qualitative and quantitative composition:||Strontium-89 chloride 37.5 MBq/ml.|
Strontium-89 is a pure beta emitter with an energy of 1.492 MeV and a half-life of 50.5 days.
|Pharmaceutical form:||Solution for injection.|
Clear, colourless solution.
|Therapeutic indications:||Strontium chloride 89SrCl2 POLATOM is indicated for the palliation of pain from bone metastases. The best documented use of strontium chloride-89 is in case of osteoblastic or mixed metastases from prostate cancer and breast cancer, it can also be used in cases of other tumorus resulting in osteoblastic (scintigraphicaly “hot”) metastases to the bone.|
Bone scintigraphy is recommended prior to Strontium-89 chloride therapy.
Most common indication for strontium chloride is the treatment of pain in patients with multiple disseminated metastases (chemotherapy, hormonal therapy, treatment with analgesics including narcotic drugs), who have not responded to previous conventional therapies).
|Shelf life:||28 days after reference date.|
|Special precautions for storage:||Store below 25ºC. Do not freeze.|
Store in accordance with national regulation on radioactive materials.
|Nature and contents of container:||The immediate packaging is a glass vial 10 ml of volume closed with a rubber stopper and aluminium cap placed in a lead container. The vial contains solution in a volume corresponding to the activity determined on the day of the calibration.|
|Enclosure||SmPC – Strontium chloride 89SrCl2 POLATOM 37.5 MBq/ml 2|